Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
SUSPENDED
NA
72 participants
INTERVENTIONAL
2006-05-31
2011-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effect of Increasing Testosterone on Insulin Sensitivity in Men With the Metabolic Syndrome
NCT00438321
Testosterone Effects on Men With the Metabolic Syndrome
NCT00382057
Effect of Testosterone Replacement on Insulin Resistance
NCT00487734
Effect of Varying Testosterone Levels on Insulin Sensitivity in Men With Idiopathic Hypogonadotropic Hypogonadism (IHH)
NCT03118479
Effect of Varying Testosterone Levels on Insulin Sensitivity in Normal and IHH Men
NCT00470990
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Seventy-two subjects will be enrolled. Study subjects will undergo a screening visit to assess eligibility after which a baseline metabolic assessment will be performed including a a fasting oral glucose tolerance test (OGTT) to measure normal glucose and insulin metabolism, an intravenous glucose tolerance test (IVGTT) to measure insulin sensitivity, MRI and DEXA scan to assess muscle and body fat distribution, VO2 max test and resting metabolic rate, and a muscle biopsy to look at how the muscle is affected by insulin and testosterone (T).
Subjects will then be randomized to one of three 12-week treatment arms, 1) Group 1 (Placebo); 2) Group 2 (Depot GnRH agonist (Zoladex) + Testosterone + placebo); or 3) Group 3 (Zoladex + Testosterone + aromatase inhibitor (anastrozole)). The rationale for this study design is as follows. Under normal physiological conditions, administration of T leads to a concomitant increase in estradiol (E2) levels due to endogenous conversion by the aromatase enzyme system. Therefore, in order to understand the relative roles of T and E2 on insulin sensitivity, one group of subjects will receive T in conjunction with the aromatase inhibitor, anastrozole.
At 13 weeks, the entire baseline evaluation including OGTT, IVGTT, resting metabolic rate and VO2 max, body composition assessment by DEXA and MRI, and muscle biopsy will be repeated. Subjects will return for a follow up visit four weeks later to measure CBC, T and PSA levels, to ensure levels are within the normal range.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1
1\) Group 1: Placebo
intravenous glucose tolerance test
The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
aerobic capacity (VO2 Max)
This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
MRI
1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
muscle biopsy
Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
measurement of resting metabolic rate (energy expenditure)
Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
Dual energy x-ray absorptiometry
Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
Fasting oral glucose tolerance test
To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
2
2\) Group 2: Depot GnRH agonist (Zoladex) + Testosterone + placebo
intravenous glucose tolerance test
The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
testosterone
transdermal 7.5 g/per day for 3 months
goserelin acetate implant
single depot injection 10.8 mg 3 months
aerobic capacity (VO2 Max)
This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
MRI
1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
muscle biopsy
Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
measurement of resting metabolic rate (energy expenditure)
Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
Dual energy x-ray absorptiometry
Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
Fasting oral glucose tolerance test
To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
3
3\) Group 3: (Zoladex + Testosterone + aromatase inhibitor (anastrozole)
intravenous glucose tolerance test
The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
testosterone
transdermal 7.5 g/per day for 3 months
anastrozole
tablet (per oral) 10.0 mg/ daily 3 months
goserelin acetate implant
single depot injection 10.8 mg 3 months
aerobic capacity (VO2 Max)
This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
MRI
1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
muscle biopsy
Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
measurement of resting metabolic rate (energy expenditure)
Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
Dual energy x-ray absorptiometry
Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
Fasting oral glucose tolerance test
To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
intravenous glucose tolerance test
The IVGTT (70) is a 4 hour study with baseline sampling for insulin and glucose, followed by the administration of 0.3 mg/kg infusion of glucose, and subsequent frequent samples through 180 minutes. At 20 minutes, subjects will receive a 0.03 U/kg infusion of regular human insulin over 45 seconds to enhance the insulin level to better help us assess the impact of insulin on glucose uptake and to facilitate minimal model analysis. The IVGTT will be administered at baseline and after 3 months.
testosterone
transdermal 7.5 g/per day for 3 months
anastrozole
tablet (per oral) 10.0 mg/ daily 3 months
goserelin acetate implant
single depot injection 10.8 mg 3 months
aerobic capacity (VO2 Max)
This test is employed to assess VO2max in all subjects. O2 and CO2 will be collected and measured from the expired air during the exercise stress test and used to calculate VO2max. This test will be administered at baseline and after 3 months.
MRI
1H-MR spectroscopy will be performed to measure IMCL at baseline and after 3 months.
muscle biopsy
Biopsies (20-50mg) will be obtained from the vastus lateralis muscle under local anesthesia (1% lidocaine) using a 5 mm Bergström needle (65) with suction applied. The muscle biopsy will be performed at baseline and after 3 months.
measurement of resting metabolic rate (energy expenditure)
Energy expenditure in the form of resting metabolic rate (RMR) will be measured via a metabolic monitor at baseline and after 3 months.
Dual energy x-ray absorptiometry
Total and regional percent body fat, fat mass, lean tissue mass and bone mineral content will be determined by DEXA (Lunar Prodigy version 8.50). DEXA provides an in vivo assessment of body composition with minimal requirements for subject cooperation and will be employed at baseline and after 3 months.
Fasting oral glucose tolerance test
To examine glucose and insulin metabolism a standard 75g OGTT will be conducted at baseline and after 3 months.
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of the metabolic syndrome defined by the American Heart Association/National Heart, Lung, and Blood Institute guidelines as the presence of three or more of the following:
* Waist circumference \> 102 cm
* Serum triglycerides \> 150 mg/dL
* HDL cholesterol \< 40 mg/dL
* Blood pressure \> 130 mm Hg systolic or 85 mm Hg diastolic, or treatment with anti-hypertensives
* Fasting serum glucose \> 100 mg/dL
* Plasma total testosterone level less than 300 ng/dL (1 SD below the mean for young healthy men)
* Stable weight for previous three months (no weight change greater than or equal to +/-10 lbs)
* Normal TSH, prolactin and prostate specific antigen (PSA) levels (\<2.5 ng/mL)
Exclusion Criteria
* Contraindication to stress testing
* Contraindication to MRI scanning (Central nervous system aneurysm clips; Implanted neural stimulator; Implanted cardiac pacemaker or defibrillator; Cochlear implant; Ocular foreign body (e.g. metal shavings); Insulin pump; Metal shrapnel or bullet)
* History of testicular disorders (i.e. cryptorchidism)
* History of bleeding disorders (i.e. thrombocytopenia) or baseline hemoglobin levels less than 12g/dL
* History of metabolic bone disease (osteoporosis, osteomalacia)
* History of prostate cancer
* History of sleep apnea (subjects will also be excluded if at their baseline assessment they admit to heavy snoring, restless sleep, and/or excessive daytime somnolence)
* Symptoms of urinary outflow obstruction (i.e. benign prostatic hypertrophy)
* Illicit drug use or heavy alcohol use (\>4 drinks/day)
* Allergic disorders
* Current medications (must exclude individuals taking the following medications):
* Testosterone,
* Cimetidine,
* Spironolactone,
* Ketoconazole,
* Finasteride,
* DHEA,
* Androstenedione,
* Oral steroids,
* GnRH analogs
50 Years
75 Years
MALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
American Diabetes Association
OTHER
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Massachusetts General Hospital, Boston MA 02114
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Frances J Hayes, MD
Role: PRINCIPAL_INVESTIGATOR
Massachusetts General Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Johns Hopkins Bayview Medical Center
Baltimore, Maryland, United States
Massachusetts General Hospital
Boston, Massachusetts, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Caronia LM, Dwyer AA, Hayden D, Amati F, Pitteloud N, Hayes FJ. Abrupt decrease in serum testosterone levels after an oral glucose load in men: implications for screening for hypogonadism. Clin Endocrinol (Oxf). 2013 Feb;78(2):291-6. doi: 10.1111/j.1365-2265.2012.04486.x.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NIDDK # 1 RO1 DK071168-01A2
Identifier Type: -
Identifier Source: secondary_id
DK71168 (suspended)
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.